Pr François Ghiringhelli

Spécialité

Oncologue médical, expert digestif

Hôpital

Centre Georges-François Leclerc (Dijon)

Derniers articles

• Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study. (4 août 2025)
• UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity. (15 juil. 2025)
• Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO. (13 juil. 2025)
• Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. (1 juil. 2025)
• Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial. (30 juin 2025)